Preliminary Results of Peg-L-Asparaginase (Oncaspar) in the Treatment of Relapsed/ Refractory Aids-Related Lymphomas.

Tulpule, Anil; Espina, Byron M.; Palmer, Maria; Schiflett, Joanne; Harvey-Buchanan, Laura; Levine, Alexandra M.

doi:10.1097/00042560-199804010-00095

Cited by 6 publications

(5 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Muss et al (Muss et al, 1990), treated 21 patients with refractory NHL with PEG-Asp and noted two PRs. Tulpule et al (Tulpule et al, 1998) treated five patients with AIDS-related lymphoma with PEG-Asp and three achieved CR. Reyes (Reyes et al, 2010) reported two patients in which PEG-Asp alone was used to treat ENKL tolerant to a CHOP regimen, and both had a CR.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

Wen

Li²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

Wen

Li²,

Li³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

“…Using this approach, Pieters and co-workers [5][6][7], as well as others [8], have documented that decreased drug sensitivity in itro, including that to ASNase, is correlated with drug resistance and poor prognosis in i o. There is a need to obtain a better understanding of the biochemical basis of ASNase resistance in ALL, and this need is underscored further by studies that have concluded that ASNase treatment may also be helpful in some adult ALL patients [9,10], in certain subgroups of childhood acute myelogenous leukaemia [11,12] and in refractory AIDS-related non-Hodgkin's lymphoma [13].…”

Section: Introductionmentioning

confidence: 99%

Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells

Aslanian¹,

Fletcher²,

Kilberg³

2001

Biochem. J.

View full text Add to dashboard Cite

Childhood acute lymphoblastic leukaemia (ALL) is treated by combination chemotherapy with a number of drugs, always including the enzyme L-asparaginase (ASNase). Although the initial remission rate is quite high, relapse and associated drug resistance are a significant problem. In vitro studies have demonstrated increased asparagine synthetase (AS) expression in ASNase-resistant cells, which has led to the hypothesis that elevated AS activity permits drug-resistant survival. The data presented show that not only is elevated AS expression a property of ASNase-resistant MOLT-4 human leukaemia cells, but that short-term (12 h) treatment of the cells with ASNase causes a relatively rapid induction of AS expression. The results also document that the elevated expression of AS in ASNase-resistant cells is not fully reversible, even 6 weeks after ASNase removal from the culture medium. Furthermore, ASNase resistance, assessed as both drug-insensitive cell growth rates and decreased drug-induced apoptosis, parallels this irreversible AS expression. Mimicking the elevated AS activity in ASNase-resistant cells by overexpression of the human AS protein by stable retroviral transformation of parental MOLT4 cells is sufficient to induce the ASNase-resistance phenotype. These data document that ASNase resistance in ALL cells is a consequence of elevated AS expression and that although other drug-induced metabolic changes occur, they are secondary to the increased asparagine biosynthetic rate.

show abstract

Section: Introductionmentioning

confidence: 99%

Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells

Aslanian

Fletcher

Kilberg

2001

Biochemical Journal

118

View full text Add to dashboard Cite

Childhood acute lymphoblastic leukaemia (ALL) is treated by combination chemotherapy with a number of drugs, always including the enzyme l-asparaginase (ASNase). Although the initial remission rate is quite high, relapse and associated drug resistance are a significant problem. In vitro studies have demonstrated increased asparagine synthetase (AS) expression in ASNase-resistant cells, which has led to the hypothesis that elevated AS activity permits drug-resistant survival. The data presented show that not only is elevated AS expression a property of ASNase-resistant MOLT-4 human leukaemia cells, but that short-term (12h) treatment of the cells with ASNase causes a relatively rapid induction of AS expression. The results also document that the elevated expression of AS in ASNase-resistant cells is not fully reversible, even 6 weeks after ASNase removal from the culture medium. Furthermore, ASNase resistance, assessed as both drug-insensitive cell growth rates and decreased drug-induced apoptosis, parallels this irreversible AS expression. Mimicking the elevated AS activity in ASNase-resistant cells by overexpression of the human AS protein by stable retroviral transformation of parental MOLT4 cells is sufficient to induce the ASNase-resistance phenotype. These data document that ASNase resistance in ALL cells is a consequence of elevated AS expression and that although other drug-induced metabolic changes occur, they are secondary to the increased asparagine biosynthetic rate.

show abstract

Preliminary Results of Peg-L-Asparaginase (Oncaspar) in the Treatment of Relapsed/ Refractory Aids-Related Lymphomas.

Cited by 6 publications

References 0 publications

Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

Efficacy and Tolerance of Pegaspargase-Based Chemotherapy in Patients with Nasal-Type Extranodal NK/T-Cell Lymphoma: a Pilot Study

Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells

Asparagine synthetase expression alone is sufficient to induce l-asparaginase resistance in MOLT-4 human leukaemia cells

Contact Info

Product

Resources

About